Oxymorphone Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 0115-1234

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxymorphone Hydrochloride (NDC 0115-1234). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Of New York Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxymorphone Hydrochloride Extended Release Tablets 1)

Chemical structure of Oxymorphone hydrochloride, showing its molecular framework including hydroxyl, methyl, and ketone groups along with its hydrochloride salt form.*

FDA Label Image

Principal Display Panel (40 mg Tablet Bottle Label)

Label for Oxymorphone Hydrochloride Extended-Release Tablets USP 40 mg by Amneal Pharmaceuticals of New York LLC. The oral, film-coated tablets are packaged as 100 count with directions for twice-a-day dosing every 12 hours. The label includes the NDC number, pharmacist instructions, a QR code for the medication guide, and storage information.*

FDA Label Image

Figure 1 (Oxymorphone Hydrochloride Extended Release Tablets 2)

A line graph comparing the percentage of patients improved against the percent of reduction or improvement in pain for Oxymorphone ER and placebo. The X-axis represents percent reduction/improvement in pain from 0 to 100%, and the Y-axis shows the percentage of patients improved from 0 to 100%. Two lines plot patient improvement for Oxymorphone ER and placebo groups respectively.*

FDA Label Image

Figure 2 (Oxymorphone Hydrochloride Extended Release Tablets 3)

A line graph comparing the percentage of patients improved versus the percent of reduction or improvement in pain for Oxymorphone ER and placebo groups. The graph shows patient improvement rates declining with increasing pain reduction thresholds, with Oxymorphone ER consistently showing higher improvement percentages than placebo across the range.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Label for Oxymorphone Hydrochloride Extended-Release Tablets, USP, 5 mg strength. The label indicates twice-a-day dosing every 12 hours, pharmacy dispensing instructions, and a count of 100 tablets. The labeler is Impax and Amneal Pharmaceuticals of New York LLC. It includes a barcode, NDC number, and storage instructions with a notice of tamper-evident packaging.*

FDA Label Image

Principal Display Panel (7.5 mg Tablet Bottle Label)

The packaging label for Oxymorphone Hydrochloride Extended-Release Tablets, USP, 7.5 mg strength. It is intended for oral use with a twice-a-day dosage every 12 hours. The label indicates a bottle of 100 tablets, marketed by Amneal Pharmaceuticals of New York LLC under the Impax brand. Additional information includes a QR code for printing the medication guide and instructions for pharmacists to dispense the guide to patients.*

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Label for Oxymorphone Hydrochloride Extended-Release Tablets, USP, 10 mg strength, oral dosage form by Amneal Pharmaceuticals of New York LLC. The label indicates a twice-a-day (every 12 hours) dosing schedule with 100 tablets per container. It includes pharmacist instructions to dispense the medication guide, storage directions, safety warnings, and a barcode with a QR code for additional information.*

FDA Label Image

Principal Display Panel (15 mg Tablet Bottle Label)

Label for Oxymorphone Hydrochloride Extended-Release Tablets, USP, 15 mg strength. The label indicates a twice-a-day dosing every 12 hours. It specifies 100 tablets in the package and is labeled by Amneal Pharmaceuticals of New York LLC under the Impax brand. The label includes the NDC 0115-1316-01, directions for the pharmacist to dispense the medication guide, storage instructions, and safety warnings.*

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Label for Oxymorphone Hydrochloride Extended-Release Tablets, USP 20 mg by Amneal Pharmaceuticals of New York LLC. The label indicates a twice-a-day (every 12 hours) oral dosing schedule and a package count of 100 tablets in bottle form. It includes storage instructions, warnings about tablet handling, and a QR code linking to the medication guide.*

FDA Label Image

Principal Display Panel (30 mg Tablet Bottle Label)

Packaging label for Oxymorphone Hydrochloride Extended-Release Tablets, USP, 30 mg strength. It is indicated for twice-a-day (every 12 hours) oral dosage, supplied in a container of 100 tablets. Labeler is Amneal Pharmaceuticals of New York LLC. Label includes NDC 0115-1317-01, usage instructions, a QR code for medication guide, and safety warnings regarding tablets being whole and not chewed or crushed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.